BioCentury | Jun 17, 2016
Company News

Management tracks

...Gene therapy play Adverum Biotechnologies Inc. (NASDAQ:ADVM) named Leone Patterson CFO. She was CFO at Diadexus Inc....
BioCentury | Oct 12, 2015
Company News

Diadexus, OriGene deal

...in diaDexus stock at about $3.82 per share, which is about a 27% premimum to Diadexus’...
...closed at $3.01 on Sept. 4, the last trading day before the deal was announced. Diadexus...
...will supply OriGene materials and reagents for PLAC ELISA on a cost plus profit basis. Diadexus...
BioCentury | Mar 3, 2015
Company News

Management tracks

...OneMed AB (Danderyd, Sweden). Lind was VP of business development at LifeCell Corp. (Branchburg, N.J.). diaDexus Inc....
BioCentury | Jan 26, 2015
Clinical News

PLAC Test for Lp-PLA2 Activity regulatory update

...Last month, FDA granted 510(k) clearance to the PLAC Test for Lp-PLA2 Activity from diaDexus as...
...measures lipoprotein-associated phospholipase A2 ( PLA2G7 ; PAFAH ; Lp-PLA2) in human plasma and serum. diaDexus Inc....
BioCentury | Jan 12, 2015
Company News

diaDexus management update

diaDexus Inc. (OTCBB:DDXS), South San Francisco, Calif. Business: Diagnostic Hired: Kenneth Fang as CMO, formerly VP of translational research and clinical development and CMO of Integrated Diagnostics Inc. Resigned: Alex Johnson as president Transitioned: Lori...
BioCentury | Sep 15, 2014
Company News

diaDexus management update

diaDexus Inc. (OTCBB:DDXS), South San Francisco, Calif. Business: Diagnostic Resigning: Jean Viret as CFO, effective Sept. 19 WIR Staff...
BioCentury | Sep 1, 2014
Financial News

diaDexus completes debt financing

...2018. The lender also received seven-year warrants to purchase up to 909,090 shares at $0.66. diaDexus...
BioCentury | Jul 28, 2014
Clinical News

PLAC Test for Lp-PLA2 Activity regulatory update

...Lp-PLA2) in human plasma and serum. The test has CE Mark approval in Europe. diaDexus’...
...aid in predicting risk for coronary heart disease (CHD) and ischemic stroke associated with atherosclerosis. diaDexus Inc....
BioCentury | Jul 14, 2014
Finance

3Q14 Financial Markets Preview: Summer lull

...intra-abdominal infections (cIAIs) and complicated urinary tract infections (cUTIs) Submit MAA; PDUFA date 2H14; 12/21/14 diaDexus Inc....
BioCentury | Jun 30, 2014
Company News

diaDexus management update

diaDexus Inc. (OTCBB:DDXS), South San Francisco, Calif. Business: Diagnostic Hired: Alexander Johnson as president, effective Aug. 4 Retiring: Brian Ward as CEO by year end Transitioning: Chairman Lori Rafield to interim executive chair WIR Staff...
Items per page:
1 - 10 of 369
BioCentury | Jun 17, 2016
Company News

Management tracks

...Gene therapy play Adverum Biotechnologies Inc. (NASDAQ:ADVM) named Leone Patterson CFO. She was CFO at Diadexus Inc....
BioCentury | Oct 12, 2015
Company News

Diadexus, OriGene deal

...in diaDexus stock at about $3.82 per share, which is about a 27% premimum to Diadexus’...
...closed at $3.01 on Sept. 4, the last trading day before the deal was announced. Diadexus...
...will supply OriGene materials and reagents for PLAC ELISA on a cost plus profit basis. Diadexus...
BioCentury | Mar 3, 2015
Company News

Management tracks

...OneMed AB (Danderyd, Sweden). Lind was VP of business development at LifeCell Corp. (Branchburg, N.J.). diaDexus Inc....
BioCentury | Jan 26, 2015
Clinical News

PLAC Test for Lp-PLA2 Activity regulatory update

...Last month, FDA granted 510(k) clearance to the PLAC Test for Lp-PLA2 Activity from diaDexus as...
...measures lipoprotein-associated phospholipase A2 ( PLA2G7 ; PAFAH ; Lp-PLA2) in human plasma and serum. diaDexus Inc....
BioCentury | Jan 12, 2015
Company News

diaDexus management update

diaDexus Inc. (OTCBB:DDXS), South San Francisco, Calif. Business: Diagnostic Hired: Kenneth Fang as CMO, formerly VP of translational research and clinical development and CMO of Integrated Diagnostics Inc. Resigned: Alex Johnson as president Transitioned: Lori...
BioCentury | Sep 15, 2014
Company News

diaDexus management update

diaDexus Inc. (OTCBB:DDXS), South San Francisco, Calif. Business: Diagnostic Resigning: Jean Viret as CFO, effective Sept. 19 WIR Staff...
BioCentury | Sep 1, 2014
Financial News

diaDexus completes debt financing

...2018. The lender also received seven-year warrants to purchase up to 909,090 shares at $0.66. diaDexus...
BioCentury | Jul 28, 2014
Clinical News

PLAC Test for Lp-PLA2 Activity regulatory update

...Lp-PLA2) in human plasma and serum. The test has CE Mark approval in Europe. diaDexus’...
...aid in predicting risk for coronary heart disease (CHD) and ischemic stroke associated with atherosclerosis. diaDexus Inc....
BioCentury | Jul 14, 2014
Finance

3Q14 Financial Markets Preview: Summer lull

...intra-abdominal infections (cIAIs) and complicated urinary tract infections (cUTIs) Submit MAA; PDUFA date 2H14; 12/21/14 diaDexus Inc....
BioCentury | Jun 30, 2014
Company News

diaDexus management update

diaDexus Inc. (OTCBB:DDXS), South San Francisco, Calif. Business: Diagnostic Hired: Alexander Johnson as president, effective Aug. 4 Retiring: Brian Ward as CEO by year end Transitioning: Chairman Lori Rafield to interim executive chair WIR Staff...
Items per page:
1 - 10 of 369